Proteomics Market Size, Share and Analysis By Component (Instrument [Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-Ray Crystallography, Surface Plasmon Resonance, Protein Fractionation, and Other Instruments], Reagents [Immunoassay Reagents, Spectroscopy Reagents, Chromatography Reagents, Protein Microarray Reagents], and Services and Software [Core Proteomics Services, and Bioinformatics Software and Services]), Application (Clinical Diagnostics, Drug Discovery), End-user Forecast, 2024-2032

Proteomics is used to identify proteins involved in a disease and study their structure, function, & expression. It helps to understand the process and interactions of the entire protein content in a specific organism. Proteomic studies also identify prognostic markers and offer diagnostics for infectious diseases like malaria and cancer. Proteomics is also used in the drug industry to investigate the mechanism of drug action or toxicity and identification and validation of the efficacy of biomarkers.

The aim of studying proteomics in the 21st century is to detect diseases at their early stages. Inordinate progress has been made in the past few years, as proteomics is a potent tool for providing information about various diseases. For instance, multiple reactions monitoring, which quantifies the proteins in the cerebrospinal fluid to detect later stages of multiple sclerosis, is a recent development in this field. Additionally, key players in the market are focused on introducing new and refined proteomics techniques, which is expected to boost the proteomics market growth. These significant drivers will continue to drive the biopharmaceutical industry's pursuit of innovative drugs and the recent technological developments in the studies of genes and proteins.

Also, collaborations among major players are becoming increasingly crucial in proteomics because it is challenging for companies to find all the necessary expertise to cover all activities involved. For instance, in September 2020, Bruker Corporation announced the acquisition of the Integrated Proteomics Pipeline (IP2) search engine and proteomics workflow software platform. IP2 was developed by Integrated Proteomics Applications Inc., which enhances Bruker’s solutions for CCS-enabled 4D-Proteomics by adding fast, scalable and GPU-based search engine capabilities for faster data processing and full utilization of molecular collision cross sections (CCS). Similarly, increased demand for personalized medicines and increased R&D in proteomics are also driving factors for the market. However, the market is expected to be constrained by certain factors like the high cost of the instruments and strict regulatory norms.

Impact of COVID-19 on the Proteomics Market

The COVID-19 outbreak is an unprecedented global public health challenge that had a measurable impact on the rapid growth of the proteomic market. Pharmaceutical companies, significant end-users of the proteomics market, limited the manufacturing of drugs due to the shortage of raw materials. Therefore, active pharmaceutical players shifted towards manufacturing essential medicines of utmost need; hence proteomics had taken a backseat in manufacturers' priorities.

However, from the first quarter of 2021, numerous proteomic labs were exploring therapeutic options, and these studies yielded potential drug targets. The new information could potentially aid the development of more rapid diagnostics for the COVID-19 virus. Therefore, the proteomics market encountered a positive impact from the increasing need to develop advanced diagnostic and therapeutic options in the wake of COVID-19. The ability of proteomics to help researchers detect several proteins in a single analysis is expected to assist in the fight against the COVID-19 virus. For instance, in Feb 2021, Agilent Technologies Inc. launched Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit to detect immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma.

Key Insights

The report will cover the following key insights:

• Key Industry Developments.


• Impact of COVID-19 On Global Proteomics Market.


• Advancements in Instruments for Proteomics Studies.


• Pharmaceutical R & D Expenditure, by Key Country.

Analysis by Component:

Based on component, the proteomics market is segmented into instruments, reagents, and services & software. The instruments segment is further sub-divided into spectroscopy, chromatography, electrophoresis, protein microarrays, x-ray crystallography, surface plasmon resonance, protein fractionation, and other instruments. By reagent, the market is sub-segmented into immunoassay reagents, spectroscopy reagents, chromatography reagents, protein microarray reagents, x-ray crystallography reagents, electrophoresis reagents, and protein fractionation reagents. Furthermore, based on services & software, the proteomics market is sub-divided into core proteomics services and bioinformatics software & services. The reagents segment is anticipated to account for a remarkable market share. The significant share of this segment can be attributed to the availability of a wide range of proteomics studies, their reliable use, and the increasing production of reagents for novel therapeutic studies by leading players in the proteomics market.

Analysis by End-user:

Based on end-user, the proteomics market is segmented into pharmaceutical and biotechnology companies, research and academic institutes, and others. The pharmaceutical and biotechnology companies are expected to account for a significant market share owing to rising R&D investments for proteomics studies and technological advances in proteomics services.

Regional Analysis:

North America is anticipated to lead the global proteomics market with a significant revenue share and is expected to flourish prominently during the analysis period. The region's significant growth is mainly attributed to the increasing investments in the development of structure-based drug design, extensive research on novel next-generation therapeutics, rising demand for high-quality research tools for data reproducibility, and growing focus on developing personalized therapeutics.

Key Players Covered:

The report will include key players such as Agilent Technologies Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., GE Healthcare (General Electric), HORIBA, Ltd., Creative Proteomics, VProteomics, Danaher Corporation, Merck KGaA, Bruker Corporation, and other prominent players.

Segmentation

Key Industry Developments

• In June 2022, SomaLogic and Illumina, Inc., announced a co-development agreement in which companies will leverage the former's SomaScan Proteomics Assay on Illumina's current and future high throughput next-generation sequencing (NGS) platforms. The partnership will accelerate next-generation sequencing into the fastest-growing area of the proteomics market with ultra-high throughput and plexity workflow.


• In February 2021, Poochon Scientific, LLC acquired a new Thermo Orbitrap Exploris 240 Mass Spectrometer with the BioPharma option and FAIMS Pro interface. It is a new-generation, versatile high-resolution mass spectrometer that delivers exceptional power for proteomics, metabolomics, and biopharmaceutical characterization.